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discomfort in EQ-5D proﬁ le responses. Sufferers’ mean pain scores on an 11-point 
Likert scale were 4.0, 5.7 and 8.6 on their best, average and worst days, respectively. 
CONCLUSIONS: Online DCEs provide a practical means to compare preferences 
between physicians and patients, whose concerns overlap substantially but are 
expressed differently. Sufferers balance pain relief and side-effects. Their refusal to 
trade between undesirable proﬁ les mirrors high reported rates of treatment 
discontinuation.
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OBJECTIVES: Multicentric Castleman’s Disease (MCD) is a rare lymphoproliferative 
disorder characterized by generalized lymphadenopathy and systemic symptoms such 
as fever, night sweats, fatigue, or loss of appetite. While many of these symptoms can 
best be assessed through patient-report there currently is no validated MCD Patient-
Reported Outcome (PRO) instrument available to evaluate symptom severity and 
response to treatment. The purpose of this study was to develop an MCD Symptom 
Scale and assess its content validity through cognitive debrieﬁ ng interviews. 
METHODS: A 16-item MCD PRO was developed through literature review, expert 
clinician input, and qualitative work with 12 patients diagnosed with MCD. Subse-
quent cognitive debrieﬁ ng was used to evaluate the content validity of the PRO with 
additional MCD patients (N = 10) 6 male, 4 female, mean age 44 years. Study pro-
cedures were IRB approved, participants provided written informed consent, inter-
views were conducted using a discussion guide, audio-recordings were transcribed, 
and data were analyzed using qualitative analysis software (Atlas.ti). RESULTS: 
Emergent discussion of symptoms demonstrated that all MCD symptoms experienced 
by patients are evaluated in the PRO. Symptom experience was variable by patient, 
supporting the 24-hour recall period for capturing patient-reported symptom severity. 
All items were consistently understood by participants, who were able to select a 
response using a 5-point response scale to represent their symptom severity experience. 
CONCLUSIONS: The MCD Symptom Scale content was found to be comprehensive. 
Design elements, including response options and recall period were suitable, and 
content validity was conﬁ rmed. The instrument was deemed acceptable for inclusion 
in clinical trials. Psychometric testing is ongoing.
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OBJECTIVES: In our hospital nearly 5000 operations are performed yearly. Based on 
document analysis, the most frequently mentioned complaint was postoperative pain 
in 48 hours following the surgery. There was no Acute Pain Service (APS) in our 
institution, neither existed a standardized professional protocol for executing postop-
erative analgesia. Our aim was to organize APS, wide-spread all over the world but 
hardly known in Hungary. METHODS: Our longitudinal, qualitative examination 
was carried out in May 2008. We investigated the data of patients regarding pain and 
analgesia at ﬁ ve operating departments via not self-ﬁ lled questionnaires and document 
analysis. Patients’ actual pain was measured before and 4th and 24th hours after the 
surgical intervention by visual analogue scale. The analgetics received after surgery 
were documented and compared to application patterns of each department. During 
evaluation T- and Chi-square probes, and variance analysis were used. RESULTS: 
Mean age of the examined sample (n = 130) is 52 years. Mean of the pain scale of 
examined patients is 3,98, higher than the internationally recommended, thus expected 
value of 3. Signiﬁ cant correlation was found (P < 0.05) between operating departments 
and applying frequency of analgetics used, as well as with mean values of the pain 
scale. Most often used medications are: noraminophenazon, tramadol and nalbuphin 
products. There is signiﬁ cant difference between pain values of patients operated at 
departments of surgery and laryngology (p = 0.048), urology and laryngology (p = 
0.036), and surgery and traumatology (p = 0.014). CONCLUSIONS: A perceptual 
form has been developed for regular documentation of pain values measured during 
resting and physical activity, beside the vital parameters, medications exhibited and 
the side-effects. Acute Pain Service (APS) has been introduced in our institution and 
standardized professional protocol has been elaborated for performing postoperative 
analgesia in accordance with preventive approach.
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OBJECTIVES: This study assesses the quantitative impact of the experience of pain 
on HRQoL for persons taking prescription pain medications in the UK, France, Spain, 
Germany and Italy. METHODS: The study is based on data from the internet based 
2008 National Health and Wellness Survey undertaken in the big 5 EU countries. This 
study identiﬁ ed some 4,503 respondents out of 11,419 who had experienced pain in 
the last month and who had reported taking prescription pain medications. The assess-
ment of the quantitative impact of pain status on HRQoL for the sub-group of pain 
respondents is estimated via three single equation generalized linear (ordinary least 
squares) models which estimate the impact of pain on PCS, MCS and utility scores. 
The model includes a range of variables which have been shown in previous popula-
tion studies to impact HRQoL. These include: socio-demographic factors, health risk 
behaviors, comorbidity status, medication utilization, duration of medication utiliza-
tion and satisfaction with care. The experience of pain is captured by a combination 
of severity and frequency categorical variables. RESULTS: The impact of pain severity 
and frequency on HRQoL for those taking prescription pain medications is substan-
tial. Compared to mild pain experienced less than weekly, the impact of severe daily 
pain is to reduce the PCS score by −14.65 points, the MCS score by −4.60 points and 
utilities by −0.15. Severe pain 4–6 times a week has an impact of −0.11 on utility and 
daily moderate pain −0.08. Overall, the impact of pain is attenuated by reduced sever-
ity and frequency. The impact of pain on HRQoL is substantially greater than the 
impact of comorbidities, duration of medication utilization, socio-demographic and 
health risk factors. CONCLUSIONS: Persons reporting utilizing prescription pain 
medications continue to experience substantial deﬁ cits in the impact of pain severity 
and frequency on HRQoL in the major EU countries.
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OBJECTIVES: The purpose of this study was to describe health-related quality of life 
(HRQL) of overweight and obese patients seeking care at the Pharmaceutical Care 
Service of the Proveeduría Farmacéutica IPP-UCV. METHODS: A convenience sample 
of 49 patients, ranging in age from 18 to 83 years was surveyed using a written 
questionnaire from February 2010 to May 2010. HRQL was measured using EuroQol 
comprising the health states descriptive system (EQ-5D) and visual analogue scale 
(EQ-VAS) as a general instrument. RESULTS: The sample consisted of 42 females 
and 7 males. The sample had a mean age of 48.55 years (s.d. 15.25 years). The mean 
weight of patients was 82.88 kg (s.d. 18.24). The mean body mass index (BMI) of 
the patients was 31.99 kg/m2 (s.d 5.77). Thirty-eight patients (77.6%) reported no 
exercising regularly. Thirty-four patients (69.4%) reported some problems with mobil-
ity. Seven patients (14.3%) reported some problems with self-care. Thirty-eight 
patients (77.6%) reported some problems with usual activity. Twenty-ﬁ ve (51%) 
patients reported some problems and 18 (36.7%) reported extreme problems with 
pain. Nineteen subjects (38.8%) reported extreme problems and 17 reported some 
problems with anxiety. CONCLUSIONS: Study limitations include the sample size 
and the use of a convenient patient sample. Overall, this exploratory study demon-
strates that nearly all aspects of HRQL are adversely affected in overweight and obese 
patients seeking care at a pharmaceutical care service in Venezuela.
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OBJECTIVES: To assess knowledge of the burden of SLE on patients. METHODS: 
A Medline search was conducted to identify relevant articles published between 2000 
and 2010 in English or non-English language. Search criteria were SLE/lupus plus one 
or more of the following terms: QoL; patient perspective; patient burden of illness/
disease; family impact/burden; prognosis; self; employment/work impact; patient(s) 
and psychological impact; patient(s) and physical impact; psychological impact; 
patient(s) and daily living/functionality; patient(s) and fatigue; impact on social life; 
patients and functioning; compared with rheumatoid arthritis/RA. Prospective studies 
involving ≥100 patients diagnosed with SLE were incorporated into the analysis. To 
focus on the burden of SLE in adult patients, studies in juvenile patients were excluded, 
as were economic analyses, studies relating to the development of HRQoL tools and 
studies of non-pharmacological interventions. RESULTS: The search identiﬁ ed 4244 
articles, 62 of which met the criteria for incorporation into the analysis. Studies 
involved a mean of 460 patients with SLE (range: 100–4,603). SLE was shown to 
affect all aspects of patients’ lives, including physical and mental health, happiness 
and relationships. Common symptoms include fatigue (50–92%), pain (71–89%), 
sleep disturbance (56–88%) and neuropsychiatric symptoms (28–80%), which all 
inﬂ uence HRQoL and work ability. Unemployment is highly prevalent among patients 
with SLE (26–54%) and can impact further on patients’ HRQoL. While most patients 
with SLE (94–100%) report unmet needs primarily reﬂ ecting physical, daily living and 
psychological concerns, physicians appear to place more emphasis on clinical and 
laboratory features. However, clinical measures of disease activity and organ damage 
are poor indicators of HRQoL. Few studies examined the effect of SLE treatment on 
HRQoL. CONCLUSIONS: SLE has a considerable impact on HRQoL and ADL. To 
improve understanding and raise awareness of the burden of SLE, further research is 
needed.
